• Non-Invasive & Safe: No risk to mother or baby — uses cell-free DNA from maternal blood.
• Early Detection: Screens for chromosomal abnormalities as early as 10 weeks into pregnancy.
• High Accuracy: Advanced NGS technology delivers high sensitivity and low false-positive rates.
• Comprehensive Screening: Detects trisomies 13, 18, 21 and sex chromosomal anomalies.
• Quick Results: Report available within 2 weeks of sample collection.
🧬 NIPT Screening Panels
Autosomal Trisomies:
Trisomy 21 (Down Syndrome), Trisomy 18 (Edwards Syndrome), Trisomy 13 (Patau Syndrome)
Sex Chromosomal Aneuploidies:
Monosomy X (Turner Syndrome), XXY (Klinefelter Syndrome), XYY, XXX
Fetal Sex Determination:
Optional fetal sex assessment from cell-free DNA
Non-Invasive Prenatal Testing (NIPT) using Next Generation Sequencing (NGS) to analyze cell-free fetal DNA (cffDNA) circulating in maternal blood. Detects copy number variants and chromosomal aneuploidies including trisomies 13 (Patau syndrome), 18 (Edwards syndrome), 21 (Down syndrome), and sex chromosomal anomalies. Requires 10 ml maternal blood in streck tube.